Alternative Choices

26/12/2025

19/12/2025

A recent Brazilian clinical trial, published in the Journal of Alzheimer’s Disease and widely reported in December 2025, marks a groundbreaking development in exploring cannabis for Alzheimer’s treatment.

Researchers at the Federal University of Latin American Integration conducted a phase 2, randomized, double-blind, placebo-controlled study involving elderly patients aged 60-80 with mild Alzheimer’s disease.

Building on prior animal studies showing low-dose THC restoring cognition in aged mice and a 2022 case report where microdosing improved symptoms in one patient over 22 months, this trial tested daily oral microdoses of a balanced cannabis extract containing approximately 0.3 mg THC and 0.3 mg CBD—far below psychoactive levels.

Over 24-26 weeks, the treatment group showed stabilized cognitive function, as measured by the Mini-Mental State Examination (MMSE), while the placebo group experienced typical decline.

This pausing of progression represents the first human trial evidence of microdosing cannabinoids potentially halting Alzheimer’s-related cognitive deterioration without significant side effects.

Described as unprecedented, the approach leverages the endocannabinoid system’s role in neuroprotection, which naturally diminishes with age. Though promising, the study’s small sample size and limited scope to certain cognitive metrics highlight the need for larger, longer trials to confirm efficacy and safety.

Current Alzheimer’s therapies offer minimal benefit and often severe side effects, making this low-risk cannabinoid option a hopeful avenue amid rising dementia cases globally.

03/12/2025

We now have B12 available..

21/11/2025

DOES THC and CBD REALLY FIGHT CANCER

THE POWER OF NATURE

Cannabinoids have anti-tumor effects by decreasing the viability, proliferation, adhesion, and migration of various cancer cells, making them an ideal cancer treatment.
https://pubmed.ncbi.nlm.nih.gov/32872551/

Medical cannabis specifically targets tumor cells but has low potency for non-tumor cells compared to traditional chemotherapy which cytotoxicity affects tumor and non-tumor cells a like.
https://pubmed.ncbi.nlm.nih.gov/32872551/

In breast cancer, THC inhibits overall cell growth and proliferation.
https://pubmed.ncbi.nlm.nih.gov/12949714/
https://pubmed.ncbi.nlm.nih.gov/32708138/

THC inhibits estradiol-induced cell proliferation by inhibiting estrogen receptor α activation.
https://pubmed.ncbi.nlm.nih.gov/18249480/

THC inhibits breast cancer proliferation at the G2/M phase via CB2 due to the downregulation of cell division control (Cdc2) which in turn induces apoptosis.
https://pubmed.ncbi.nlm.nih.gov/32708138/
https://pubmed.ncbi.nlm.nih.gov/16818634/

In vivo, THC reduces ErbB2-driven metastatic breast cancer growth and reduces metastasis to the lung.
https://pubmed.ncbi.nlm.nih.gov/20649976/

THC inhibits the heterodimerizations of HER2 and CB2 preventing the tumorigenesis of breast cancer in vitro and vivo.
https://pubmed.ncbi.nlm.nih.gov/32708138/
https://pubmed.ncbi.nlm.nih.gov/30733293/

Furthermore, in vivo THC significantly reduces tumor growth and decreased the expression of the HER2 protein.
https://pubmed.ncbi.nlm.nih.gov/32708138/
https://pubmed.ncbi.nlm.nih.gov/30733293/

Effects of CBD in vitro and in vivo in breast cancer.
https://pubmed.ncbi.nlm.nih.gov/32708138/

CBD induces apoptosis and autophagy via reactive oxygen species (ROS) production causing endoplasmic reticulum stress apoptosis in select breast cancer cells.
https://pubmed.ncbi.nlm.nih.gov/21566064/

CBD inhibits epidermal growth factor (EGF)-induced proliferation, migration, and invasion of breast cancer cells.
https://pubmed.ncbi.nlm.nih.gov/25660577/

CBD significantly reduces migration, invasion, and expression of malignant markers as well as promotes the recovery of cell contacts in 6D, the invasive mesenchymal-like phenotype in MCF-7, breast cancer cells.
https://pubmed.ncbi.nlm.nih.gov/32244518/

CBD also increases sensitivity to anti-cancer drugs doxorubicin and cisplatin in 6D cells by downregulating the expression of resistance proteins.
https://pubmed.ncbi.nlm.nih.gov/32244518/

CBD also increases sensitivity to anti-cancer drugs doxorubicin and cisplatin in 6D cells by downregulating the expression of resistance proteins.https://pubmed.ncbi.nlm.nih.gov/32244518/
CBD reduces advanced-stage breast cancer metastasis via the downregulation of the Inhibitor of DNA binding protein 1 (Id1), a transcriptional factor and marker for breast cancer cell metastasis to the lung.
https://pubmed.ncbi.nlm.nih.gov/24910342/

CBD also reduces the proliferation and invasion of breast cancer cells by reducing the expression of Id-147
https://pubmed.ncbi.nlm.nih.gov/16078104/

Endocannabinoids have also inhibited the growth of PC3 prostate cancer cells via inhibiting adenylate cyclase and protein kinase A activity, arresting the cell cycle via the induction of p27 and downregulation of the EGF receptor.
https://pubmed.ncbi.nlm.nih.gov/32872551/
https://pubmed.ncbi.nlm.nih.gov/25606819/

Endocannabinoids have inhibited the growth and induces apoptosis in primary prostate tumors via activation of the ERK signaling pathway.
https://pubmed.ncbi.nlm.nih.gov/32872551/
https://pubmed.ncbi.nlm.nih.gov/25606819/

Phytocannabinoids THC and CBD have been shown to reduce prostate cancer cell viability by inducing apoptosis.
https://pubmed.ncbi.nlm.nih.gov/22594963/

THC induces apoptosis in a dose-dependent and cannabinoid receptor-independent manner in prostate cancer cells.
https://pubmed.ncbi.nlm.nih.gov/10570948/

CBD inhibits prostate cancer cell growth via the induction of intrinsic pathways of apoptosis, cell cycle arrest at the G1-S phase, and activation of p53 and elevated ROS levels.
https://pubmed.ncbi.nlm.nih.gov/22594963/

CBD when used in combination with anti-cancer drugs, Docetaxel and Bicalutamide, can effectively inhibit tumor growth in vivo and vitro.
https://pubmed.ncbi.nlm.nih.gov/22594963/

Conclusion
Cannabinoids employ anti-tumorigenic effects on various tumor types. Cannabinoids have been proven to be tumor suppressors affecting proliferation, migration, and invasion inducing apoptosis and autophagy. Cannabinoids also regulate vital processes that are essential physiologically and biologically such as cell homeostasis, cell motility, inflammation, pain-sensation, mood, and memory.

These data support the clinical testing of CBD against prostate carcinoma.

08/11/2025

Clinical Trial: Cannabis Extract Demonstrates Superiority Over Opioids in Patients With Chronic Back Pain
BY NORML POSTED ON OCTOBER 3, 2025
cannabis oil extract
Plant-derived cannabis extracts provide superior relief and offer other clinically meaningful advantages over opioids in patients suffering from chronic low back pain, according to clinical trial data published in the journal Pain and Therapy.

A team of German investigators compared the safety and efficacy of a proprietary cannabis extract (VER-01) containing 2.5 mg of THC and standardized percentages of CBD and CBG (cannabigerol) to commercially available opioids in a cohort of 392 older adults with intractable lower back pain. Study participants were randomly designated to use either opioids or cannabis extracts for six months.

Patients taking cannabis extracts experienced greater short-term and long-term pain relief, as well as superior sleep quality, researchers reported. Specifically, participants receiving extracts experienced a mean pain reduction of 2.33 points on an 11-point numeric rating scale, compared with a 1.89-point reduction in the opioid group.

Those who consumed opioids were far more likely to experience constipation as compared to those taking cannabis extracts. Participants who consumed extracts did not experience withdrawal symptoms following the study’s conclusion.

“In summary, this study provides robust evidence that VER-01 [plant-derived cannabis extracts] offers better tolerability, as well as superior pain relief and sleep quality compared to opioids in patients with CLBP [chronic low back pain],” the study’s authors concluded. “These findings position VER-01 as a promising, non-addictive, well-tolerated, and effective alternative, particularly for long-term use, [and they] … highlight its potential as a promising new pharmacological option within a multimodal treatment approach that could fundamentally shift the paradigm in the treatment of chronic pain.”

Commenting on the study’s findings, NORML’s Deputy Director said: “These results affirm the longstanding experiences of patients, many of whom either reduce or eliminate their use of opioids after initiating cannabis therapy because they perceive cannabis to be a safer and more effective alternative.”

Researchers previously published data showing that VER-01 is superior to placebo in mitigating chronic low back pain. Other studies have shown that patients with lower back pain reduce their use of opioids following the initiation of medical cannabis therapy.

01/11/2025

Serrapeptase.

31/10/2025

Special offer for one week only.

One gram of herb free with every bottle of cbd purchased..